Dr.Unnikrishnan Nair R
The introduction of Anti Vascular Endothelial Growth Factors (Anti VEGF) drugs have revolutionized the limits to which the treatment of vascular chorio-retinal pathology can be taken. However from the exultation of the early days, now a sober realization and understanding of the limitations and applications of anti VEGF agents is evolving. Numerous new concepts, drugs and adjuncts have been incorporated into the management creating new scenarios previously not considered. Adding to this, there are practical difficulties of repetitive usage , concerns about safety and data from trials that affect treatment decisions and outcomes. This course looks at the important facts on how to safely use Bevacizumab in your practice, real life issues about the usage of Anti VEGF in DME and PDR , Anti VEGF alternatives and additives , the role of Anti VEGF in ROP and a reality check on how to use Anti VEGF optimally in AMD.
| 1 | The ethically and legally safe way to administer intravitreal Bevacizumab (10 mins) | Dr.Manoj S | watch video | |
| 2 | Managing Patient expectations and outcomes during repetitive use of AntiVEGF in DME (10 mins) | Dr.Rupak Kanti Biswas | watch video | |
| 3 | PDR -Travel along the PRP highway or take an Anti VEGF detour (10 mins) | Dr.Sunil Ganekal | watch video | |
| 4 | Anti VEGF in ROP – A Premature Panacea? (10 mins) | Dr.Maneesh Bapaye | watch video | |
| 5 | Do you really know when “enough is enough” in AMD (10 mins) | Dr.Rajeev Jain | watch video | |
| 6 | SWITCH OR ADD – When you have to replace or add while on Anti VEGF therapy (10 mins) | Dr.Unnikrishnan Nair R | watch video | |
| Panel Discussion : (10 mins.) | ||||
| Keynote Address : Surviving the Epidemic of Intravitreal Injections | Dr. Kamal Kishore | watch video |
Leave a Comment